Search - tctmd.com

Displaying 141 - 160 of 202

Sort: Relevancy | Date

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

News Daily News

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

Caitlin E. Cox

March 24, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Daily News

CABANA Supports Use of AF Ablation in Patients With Heart Failure

Todd Neale

February 12, 2021

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

L.A. McKeown

February 04, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

L.A. McKeown

January 11, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

More Women Than Men Develop HF or Die After STEMI

L.A. McKeown

December 01, 2020

News Daily News

New Review Urges Rethink of Cardiogenic Shock Care

Caitlin E. Cox

October 27, 2020

News Daily News

More Than Half of All HF Patients Take 10 or More Meds

L.A. McKeown

October 20, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

Michael O'Riordan

August 13, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Race and Gender Bias May Sway Decisions in Advanced HF Care

L.A. McKeown

July 21, 2020

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

L.A. McKeown

March 20, 2020

News Daily News

New Review Tracks ‘Evolving’ CV Impact of COVID-19 on Patients, Hospitals

Michael O'Riordan

March 20, 2020

Advertisement

FDA Approves Dapagliflozin for CKD Patients

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

CABANA Supports Use of AF Ablation in Patients With Heart Failure

Did Regional Differences Muddy Results in COMMANDER-HF?

FDA Approves Vericiguat for High-risk Patients With HF

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

More Women Than Men Develop HF or Die After STEMI

New Review Urges Rethink of Cardiogenic Shock Care

More Than Half of All HF Patients Take 10 or More Meds

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Race and Gender Bias May Sway Decisions in Advanced HF Care

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Missed Opportunities: Many HF Patients Not Tested for CAD

New Review Tracks ‘Evolving’ CV Impact of COVID-19 on Patients, Hospitals

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content